UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Quarterly Period Ended June 30, 2004
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Transition Period From to
Commission File Number 000-49871
HEALTHETECH, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 77-0478611 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. employer identification no.) | |
| 523 Park Point Drive, 3rd Floor, Golden, Colorado |
80401 | |
| (Address of principal executive office) | (Zip code) | |
Registrants telephone number, including area code: (303) 526-5085
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x
As of August 6, 2004, the number of shares outstanding of the registrants common stock, par value $0.001 per share, 7,086,215.
| Page | ||||
| PART I. | FINANCIAL INFORMATION | 1 | ||
| Item 1. | Unaudited Financial Statements | 1 | ||
| Unaudited Balance Sheets | 1 | |||
| Unaudited Statements of Operations | 2 | |||
| Unaudited Statements of Cash Flows | 3 | |||
| Notes to Unaudited Financial Statements | 4 | |||
| Item 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations | 9 | ||
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 15 | ||
| Item 4. | Controls and Procedures | 15 | ||
| PART II. | OTHER INFORMATION | 15 | ||
| Item 1. | Legal Proceedings | 15 | ||
| Item 2. | Changes in Securities and Use of Proceeds | 15 | ||
| Item 3. | Defaults Upon Senior Securities | 16 | ||
| Item 4. | Submission of Matters to a Vote of Security Holders | 16 | ||
| Item 5. | Other Information | 16 | ||
| Item 6. | Exhibits and Reports on Form 8-K | 17 | ||
| SIGNATURES | 18 | |||
| EXHIBIT INDEX | 19 | |||
ITEM 1. Unaudited Financial Statements
HEALTHETECH, INC.
Balance Sheets
| December 31, 2003 |
June 30, 2004 |
||||||
| (unaudited) | |||||||
| ASSETS |
|||||||
| Current assets: |
|||||||
| Cash and cash equivalents |
$ | 17,003,224 | 12,762,288 | ||||
| Receivables, net of allowance of $307,000 and $307,000 respectively |
620,428 | 555,839 | |||||
| Inventory |
1,908,233 | 1,708,272 | |||||
| Prepaid expenses |
676,360 | 305,681 | |||||
| Other current assets |
17,979 | 54,560 | |||||
| Total current assets |
20,226,224 | 15,386,640 | |||||
| Property and equipment, net |
1,843,841 | 1,332,355 | |||||
| Deposits |
266,398 | 265,313 | |||||
| Intangible assets, net of accumulated amortization of $2,796,970 and $2,895,988 in 2003 and 2004, respectively |
1,555,742 | 1,498,633 | |||||
| TOTAL ASSETS |
$ | 23,892,205 | 18,482,941 | ||||
| LIABILITIES & STOCKHOLDERS EQUITY |
|||||||
| Current liabilities: |
|||||||
| Accounts payable |
$ | 567,479 | 326,875 | ||||
| Accrued liabilities |
1,052,133 | 618,157 | |||||
| Deferred revenue |
71,657 | 65,183 | |||||
| Total current liabilities |
1,691,269 | 1,010,215 | |||||
| Other liabilities |
171,640 | 93,250 | |||||
| Total liabilities |
1,862,909 | 1,103,465 | |||||
| Stockholders equity: |
|||||||
| Common stock, $0.001 par value, 100,000,000 shares authorized; 7,041,954 and 7,086,215 shares issued and outstanding in 2003 and 2004, respectively |
7,042 | 7,086 | |||||
| Deferred stock-based charges |
(1,817,371 | ) | (1,676,731 | ) | |||
| Additional paid-in capital |
114,764,010 | 115,552,559 | |||||
| Accumulated deficit |
(90,924,385 | ) | (96,503,438 | ) | |||
| Total stockholders equity |
22,029,296 | 17,379,476 | |||||
| Commitments and contingencies |
|||||||
| TOTAL LIABILITIES & STOCKHOLDERS EQUITY |
$ | 23,892,205 | 18,482,941 | ||||
The accompanying notes are an integral part of these unaudited financial statements.
1
HEALTHETECH, INC.
Statements of Operations
Unaudited
| Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
| 2003 |
2004 |
2003 |
2004 |
|||||||||||||
| Revenue: |
||||||||||||||||
| Product and measurement sales |
$ | 675,235 | $ | 791,079 | $ | 1,603,353 | $ | 1,403,042 | ||||||||
| Software and other |
533,185 | 249,676 | 1,223,123 | 376,960 | ||||||||||||
| Total revenue |
1,208,420 | 1,040,755 | 2,826,476 | 1,780,002 | ||||||||||||
| Cost of revenue: |
||||||||||||||||
| Product and measurement sales |
677,370 | 669,915 | 1,549,084 | 1,132,116 | ||||||||||||
| Software and other |
459,895 | 132,433 | 733,415 | 307,536 | ||||||||||||
| Stock-based charges |
2,631 | 7,257 | 51,146 | 25,037 | ||||||||||||
| Total cost of revenue |
1,139,896 | 809,605 | 2,333,645 | 1,464,689 | ||||||||||||
| Gross profit |
68,524 | 231,150 | 492,830 | 315,314 | ||||||||||||
| Operating expenses: |
||||||||||||||||
| Research and development, excluding $101,295, $112,668, $680,740, and $295,492 of stock-based charges for the three months ended June 30, 2003 and 2004 and the six months ended June 30, 2003 and 2004, respectively |
1,681,133 | 718,297 | 4,115,953 | 1,503,829 | ||||||||||||
| Selling, general and administrative, excluding $390,109, $202,487 $1,279,010, and $520,320 of stock-based charges for the three months ended June 30, 2003 and 2004 and the six months ended June 30, 2003 and 2004, respectively |
2,843,581 | 1,689,695 | 10,333,790 | 3,277,586 | ||||||||||||
| Restructuring charges and asset impairment |
2,114,026 | 105,102 | 2,114,026 | 377,159 | ||||||||||||
| Stock-based charges |
491,404 | 315,155 | 1,959,750 | 815,812 | ||||||||||||
| Total operating expenses |
7,130,144 | 2,828,248 | 18,523,520 | 5,974,386 | ||||||||||||
| Loss from operations |
(7,061,620 | ) | (2,597,099 | ) | (18,030,690 | ) | (5,659,073 | ) | ||||||||
| Interest income |
51,115 | 36,698 | 124,169 | 80,842 | ||||||||||||
| Interest expense |
(1,575 | ) | (120 | ) | (3,466 | ) | (822 | ) | ||||||||
| Net loss |
$ | (7,012,080 | ) | $ | (2,560,520 | ) | $ | (17,909,986 | ) | $ | (5,579,053 | ) | ||||
| Basic and diluted loss per common share: |
$ | (1.79 | ) | $ | (.36 | ) | $ | (4.57 | ) | $ | (.79 | ) | ||||
| Basic and diluted weighted average number of shares outstanding |
3,923,058 | 7,082,744 | 3,920,341 | 7,073,066 | ||||||||||||
The accompanying notes are an integral part of these unaudited financial statements.
2
HEALTHETECH, INC.
Statements of Cash Flows
Unaudited
| Six months ended |
||||||||
| June 30, 2003 |
June 30, 2004 |
|||||||
| Cash flows from operating activities: |
||||||||
| Net loss |
$ | (17,909,986 | ) | $ | (5,579,053 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
| Depreciation and amortization |
1,097,325 | 672,922 | ||||||
| Intangible asset impairment |
1,584,600 | | ||||||
| Inventory reserves and write-offs |
294,072 | 846 | ||||||
| Loss on disposal of property and equipment |
| 73,545 | ||||||
| Stock-based charges |
2,010,897 | 840,849 | ||||||
| Provision for doubtful accounts |
65,000 | | ||||||
| Change in assets and liabilities: |
||||||||
| Receivables |
2,329,027 | 64,589 | ||||||
| Inventory |
(139,105 | ) | 199,115 | |||||
| Prepaid expenses and other current assets |
2,724,198 | 334,098 | ||||||
| Deposits |
1,050 | 1,085 | ||||||
| Accounts payable |
(1,337,676 | ) | (240,604 | ) | ||||
| Accrued and other liabilities |
(39,236 | ) | (512,366 | ) | ||||
| Deferred revenue |
(319,693 | ) | (6,474 | ) | ||||
| Net cash used in operating activities |
(9,639,527 | ) | (4,151,447 | ) | ||||
| Cash flows from investing activities: |
||||||||
| Purchase of property and equipment |
(307,019 | ) | (135,962 | ) | ||||
| Proceeds from the sale of marketable securities |
3,836,711 | | ||||||
| Purchase of intangible assets |
(166,225 | ) | (41,909 | ) | ||||
| Net change in restricted cash |
(252 | ) | | |||||
| Net cash provided by (used in) investing activities |
3,363,215 | (177,872 | ) | |||||
| Cash flows from financing activities: |
||||||||
| Payments on note payable to related party |
(10,000 | ) | | |||||
| Common stock issuance costs |
| (22,865 | ) | |||||
| Proceeds from common stock option exercises |
106,135 | 111,248 | ||||||
| Net cash provided by financing activities |
96,135 | 88,383 | ||||||
| Net decrease in cash and cash equivalents |
(6,180,177 | ) | (4,240,936 | ) | ||||
| Cash and cash equivalents, beginning of period |
16,878,263 | 17,003,224 | ||||||
| Cash and cash equivalents, end of period |
$ | 10,698,086 | $ | 12,762,288 | ||||
The accompanying notes are an integral part of these unaudited financial statements.
3
HEALTHETECH, INC.
UNAUDITED NOTES TO FINANCIAL STATEMENTS
(1) Business and Basis of Financial Statement Presentation
HealtheTech, Inc. (the Company or HealtheTech) was incorporated in February 1998 under the laws of the State of Delaware. The Company operates in one segment and develops and markets health solutions designed to give consumers simple, informative ways to improve and maintain health and wellness.
The accompanying financial statements as of June 30, 2004 and for the three months and six months ended June 30, 2003 and 2004 are unaudited and have been prepared in accordance with generally accepted accounting principles on a basis consistent with the December 31, 2003 audited financial statements and include normal recurring adjustments which are, in the opinion of management, necessary for a fair statement of the results of these periods. These statements should be read in conjunction with our financial statements and notes thereto included in our Form 10-K (Commission File No. 000-49871), filed on March 29, 2004. Operating results for the three months and six months ended June 30, 2004 are not necessarily indicative of the results that may be expected for the full year.
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.
The Companys financial statements are based on several significant estimates, including the reserve for warranty obligations and product returns, provision for excess and obsolete inventory, provision for doubtful accounts and the estimated useful lives of long-lived assets, as well as the recoverability of the investment in long-lived assets.
(2) Significant Accounting Policies
(a) Cash and Cash Equivalents and Restricted Cash
All highly liquid investments purchased with original maturities of three months or less are considered to be cash equivalents.
(b) Reclassifications
Certain reclassifications have been made to prior period financial statements to conform to the 2004 presentation.
(c) Inventory
Inventory is stated at the lower of cost or market, using the first-in, first-out method and consists of purchased items or finished goods that were manufactured internally or for the Company by contract manufacturers. Our strategy utilizes both in-house and outsourced manufacturing, warehousing and shipping of our health monitoring devices, disposables and software to benefit from the resources of our contract manufacturers and fulfillment vendor where appropriate, in order to minimize the overall costs of our products. We rely on contractors for the manufacture, warehousing and shipping of the component parts for our devices.
(d) Intangible Assets
Intangible assets consist of purchased patents and legal fees to obtain patents and are recorded at cost. Amortization of intangible assets is calculated using the straight-line method over the estimated useful lives, generally five to ten years. Amortization expense was $132,244 and $50,074 for the three months ending June 30, 2003 and 2004, respectively and $276,490 and $99,018 for the six months ending June 30, 2003 and 2004, respectively. The Company periodically evaluates the recoverability of intangible assets and takes into account events and circumstances that warrant revised estimates of useful lives or that indicate that impairment exists.
(e) Accrued liabilities
Accrued liabilities consist of the following:
| December 31, 2003 |
June 30, 2004 | |||||
| (unaudited) | ||||||
| Customer deposit |
$ | 123,842 | ||||